atugen AG is a technology leader in disease pathway elucidation. Building on successful high profile collaborations, atugen is positioned to take advantage of the industry´s need to unravel the function of genes and to dissect signal transduction pathways. atugen has already proven its ability by building a portfolio of functionally validated targets and inhibitor compounds of the PI 3-kinase pathway, which plays an important role in most cancer types, diabetes, wound healing and other indications.
The company offers proprietary KnockDown™ technologies such as antisense molecules (so called GeneBlocs®), improved synthetic siRNA, vector expression systems for siRNA and ribozymes, and superior transfection reagents. atugen has entered into various partnerships with major pharmaceutical and biotechnology companies ranging from a fee-for-service structure to strategic alliances to discover and validate gene targets for drug discovery. atugen´s customers include: Agouron Pharmaceuticals, Altana Pharma, Arena Pharmaceuticals, AstraZeneca, Axys Pharmaceuticals, Bayer, Boehringer Ingelheim, Kinetek, Millennium Pharmaceuticals, Novo Nordisk, Oxford Glycosciences, Pfizer, Roche Biosciences, Schering AG/Berlex Biosciences, Serono and UCSF.